Nerea Alonso

Innovation Manager at Fundación Biomedica Galicia Sur

Spain · VigoJoined April 2020

Summary

The Galicia Sur Health Research Institute (IISGS) was created in 2008 after a cooperation agreement was signed between the Ministry of Health, the Galician Healthcare Service and the University of Vigo. Its creation responds to the strategy promoted by the Carlos III Health Institute (ISCIII) for the development of Health Research Institutes as organizational structures for the promotion and development of research in hospitals.

The IISGS has configured itself as a space for multidisciplinary research in Biomedicine based in the Álvaro Cunqueiro Hospital in Vigo which brings together the clinical research groups from the Health Areas in the South of Galicia and the biotech groups of the University of Vigo. Its primary objective is to promote translational research and innovation, and thus ensure the effective application of research results in order to improve the health of its citizens.

The Galicia Sur Biomedical Foundation is the managing entity of the IISGS, and it is in charge of the comprehensive management of research, development and technological innovation projects being developed by the research groups that are part of the Institute.

Research areas of interest (3)

  • Biological Sciences
  • Medicine, Human Health
  • Medical Research

Nerea Alonso didn't publish any Technology Call yet

A new family of galactose analogues (PBX) is proposed as a possible treatment of FD and other LSDs. PBX acts as stabilizer of the α-GalA in the presence of mutations that affect its folding.[…]

A new family of galactose analogues (PBX) is proposed as a possible treatment of FD and other LSDs. PBX acts as stabilizer of the α-GalA in the presence of mutations that affect its folding.[…]

It is proposed an in vitro method for the diagnosis or prognosis of neurodegenerative disorders based on a new 48 KDa fragment of LRP1 (48 KDa – LRP1), wherein if the ratio of 48 KDa – LRP1 / proLRP1 level is significantly higher as compared with the level measured in healthy controls, this is indic[…]

Use of a new species of streptococcus, Streptococcus downii, and/or bioactive compounds derived from it for the treatment of infections of the oral cavity, such as caries and periodontitis. S. downii belongs to the group of healthy commensal oral streptococci.[…]

Nerea Alonso didn't publish any Paper yet

Nerea Alonso didn't publish any Event yet

Nerea Alonso didn't publish any Job yet

Nerea Alonso didn't publish any New and Article yet

Nerea Alonso didn't publish any Education Resource yet

You are signed out

Join Innoget to connect with Nerea Alonso and thousands
of innovation-driven professionals and organizations